V-Con: Medical cannabis – green grass, green growth
Link copied to
V-Con is Stockhead’s investing focused video conference series, bringing you expert insights, panel discussions and presentations from leading analysts, listed small caps and industry players.
This latest video conference focuses on the cannabis sector.
Attitudes towards marijuana have shifted rapidly in the last six years as a number of US states legalised the drug without experiencing social problems. Here in Australia, the Turnbull government kicked off the industry with the legalisation of medical marijuana in 2016.
According to cannabis consultancy Freshleaf Analytics, industry revenue tripled in 2020 to around $95 million, with the number of products available on the market doubling to 150.
In a major shift, this month the Therapeutic Goods Administration began accepting applications for low-dose CBD oils and pills to be listed on the Australian Register of Therapeutic Goods as Schedule 3 drugs, meaning they could be obtained from a pharmacist without a prescription. Currently access to legal cannabis requires a script from a doctor, and FreshLeaf estimates there’s 30,000 Australian patients currently with one.
This year could also be a turning point for the industry as a supply glut and aggressive pricing shakes out the high-cost cannabis growers.
But a number of medical marijuana companies have turned to using the hitherto under-studied cannabis as a treatment for everything from insomnia and anxiety to infections and acne. Several clinical trials are underway or planned to begin shortly.
To get a gauge on the green growth industry, we hear from experts and a selection of listed companies making waves in the sector, each giving an overview of their treatments, therapeutics, technologies and future plans.
Sky News and CNBC business journalist Oriel Morrison interviews Mark Bernberg, founder of The Green Fund.
Mark Bernberg is a long-time cannabis investing enthusiast and founder of The Green Fund, Asia Pacific’s preeminent media house, positioned at the forefront of the global cannabis industry.
Creso Pharma Ltd (ASX: CPH) and subsidiary Mernova Medicinal Inc.
Jorge Wernli, Director at Creso Pharma & Jack Yu, Managing Director of Mernova Medicinal Inc.
Creso was created to bring pharmaceutical expertise and methodological rigour to the world of cannabis and deliver quality products to people and animals everywhere. Mernova Medicinal Inc. is Creso’s wholly owned Canadian subsidiary, licensed by Health Canada to cultivate and sell cannabis. Home of the Ritual Green brand of premium cannabis products.
MMJ Group Holdings Ltd (ASX:MMJ)
Michael Curtis, Non-Executive Director of MMJ Group Holdings and Director of Parallax Ventures.
MMJ’s core business is holding minority investments along the cannabis value-chain including cultivation, extraction, crystallisation, product manufacture, retail and patient services in Australia, Canada and Europe.
MGC Pharmaceuticals Ltd (ASX:MXC)
Nicole Godresse, Global Chief Sales Officer
MGC is a biopharma company with a “Nature to Medicine” strategy at the forefront of the emerging phytocannabinoid and plant derived medicine markets.
Christopher Strauch, Managing Director
Montu develops innovative cannabis medications and makes them accessible to patients through a nationwide network of doctors.
Botanic Wellness Limited
Cary Stynes, Executive Chairman
Botanic Wellness has operations in Colorado, Arizona and Texas in the USA and NSW in Australia growing various strains of CBD hemp seeds, planting and harvesting CBD hemp crops for the flower, seeds and fibre and extracting and processing CBD for wholesale and retail sale in the USA, Europe and Australia and is expanding into Asia.